Silexion Therapeutics Corp(SLXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLXN Silexion Therapeutics Corp

Post-Mkt 08-26 16:32:08 EDT

0.3549

-0.0101

-2.77%

盘后0.3600

+0.0051+1.44%

16:21 EDT

High0.3740	Low0.3506	Vol221.09K
Open0.3740	D1 Closing0.3650	Amplitude6.41%
Mkt Cap1.97M	Tradable Cap1.95M	Total Shares5.56M
T/O78.91K	T/O Rate4.03%	Tradable Shares5.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":0.3549,"timestamp":1787774400000,"preClose":0.365,"halted":0,"volume":221093,"hourTrading":{"tag":"盘后","latestPrice":0.36,"preClose":0.3549,"latestTime":"16:21 EDT","volume":115,"amount":41.389500500000004,"timestamp":1787775683901,"change":0.0051,"changeRate":0.01437,"amplitude":0.018597},"delay":0,"changeRate":-0.027671232876712325,"floatShares":5482205,"shares":5560300,"eps":-56.4473,"marketStatus":"Post-Mkt","change":-0.0101,"latestTime":"08-26 16:32:08 EDT","open":0.374,"high":0.374,"low":0.3506,"amount":78913,"amplitude":0.06411,"askPrice":0.39,"askSize":270,"bidPrice":0.351,"bidSize":2592,"shortable":3,"etf":0,"ttmEps":-56.4473,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787788800000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.365,"preHourTrading":{"tag":"盘前","latestPrice":0.3656,"preClose":0.365,"latestTime":"09:08 EDT","volume":3400,"amount":1235.082062,"timestamp":1787749696403,"change":0.0006,"changeRate":0.001644,"amplitude":0.02137},"postHourTrading":{"tag":"盘后","latestPrice":0.36,"preClose":0.3549,"latestTime":"16:21 EDT","volume":115,"amount":41.389500500000004,"timestamp":1787775683901,"change":0.0051,"changeRate":0.01437,"amplitude":0.018597},"volumeRatio":0.857694},"requestUrl":"/m/hq/s/SLXN/wiki","defaultTab":"wiki","newsList":[{"id":"2662737518","title":"After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662737518","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662737518?lang=en_us&edition=fundamental","pubTime":"2026-08-25 21:00","pubTimestamp":1787662814,"startTime":"0","endTime":"0","summary":"WSW, NY, August 25th, 2026, FinanceWire Moderna’s cancer news sent its stock up 177% in a single day (NASDAQ:MRNA), from $62.96 to $174.38. Roughly...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/after-modernas-44b-oncology-win-silexions-pancreatic-cancer-treatment-is-worth-exploring-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/after-modernas-44b-oncology-win-silexions-pancreatic-cancer-treatment-is-worth-exploring-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQQ","FTEC","MRNA","QDTE","BK4139","NVIW.SI","QQQY","MRNY","BK4532","QLD","QQQA","LGHT","BK4534","SQQQ","SLXN","BK4568","GPIQ","QID","BK4548","IDNA","PSQ","QQQJ","BK4585","NDX","TQQQ","BK4588","JEPQ","BK4551","WDNA",".IXIC","BK4501","BK4533","IYW","ONEQ","MRNX","QQQM","TQQY","MNQmain","QYLG","QQQE","GNOM","TECS","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662323217","title":"Silexion Therapeutics Announces Extraordinary Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2662323217","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662323217?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:37","pubTimestamp":1787661459,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics announces extraordinary shareholder meetingSilexion Therapeutics will hold an extraordinary general meeting in Ramat Gan, Israel on Sept. 9, 2026.Shareholders will vote on increasing authorized share capital by 175,000,000 ordinary shares to 190,900,000 shares.A separate proposal seeks approval for a reverse share split at a ratio between 1-for-7 and 1-for-15.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nNDL80SMdr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661297157","title":"Silexion Therapeutics Faces NASDAQ Delisting Notice over Minimum Shareholders’ Equity Shortfall","url":"https://stock-news.laohu8.com/highlight/detail?id=2661297157","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661297157?lang=en_us&edition=fundamental","pubTime":"2026-08-22 04:21","pubTimestamp":1787343712,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics faces Nasdaq delisting notice over minimum shareholders’ equity shortfallNasdaq issued a delisting notice on Aug. 18, 2026 over non-compliance with the $2.5 million minimum share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL8bv9x1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660542263","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (ATAI), InspireMD (NSPR) and Silexion Therapeutics (SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660542263","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660542263?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:30","pubTimestamp":1787157016,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Atai Beckley N.V. (ATAI), InspireMD (NSPR) and Sil...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-atai-beckley-n-v-atai-inspiremd-nspr-and-silexion-therapeutics-slxn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-atai-beckley-n-v-atai-inspiremd-nspr-and-silexion-therapeutics-slxn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","NSPR","BK4007","BK4588","XLV","BK4581","BK4198","BK4139","LABU","XBI","BK4585","LU0029874061.USD","BK4539","SLXN","ATAI","LU0128526141.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129788","title":"Silexion Therapeutics Announces Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129788","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129788?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:34","pubTimestamp":1786739654,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics announces extraordinary general meetingSilexion Therapeutics will hold an extraordinary general meeting in September 2026 at Meitar Law Offices in Ramat Gan, Israel.Shareholders ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL4zZPVy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659419521","title":"Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659419521","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659419521?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:45","pubTimestamp":1786711501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUAC8WBH0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659092299","title":"U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2659092299","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659092299?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:17","pubTimestamp":1786551433,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sutro Biopharma, HumacyteAugust 12 (Reuters)-Wall Street's main indexes rose on Wednesday, with the Nasdaq outperforming peers as upbeat earnings from AI infrastructure fi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL6N4490YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EAT","TAN","LAZR","CRWV","UAMY","STRO","DFTX","UFO","SMCI","LOCL","ALT","HRB","SVV","LQDA","CHTR","EROC","LUMA","PFGC","SLXN","TECH","TRMB","NTHI","NBIS","SMWB","DPRE","NCMI","SLNCF","OFAL","SMCL","CIEN","FSLR","SMMT","SLN","CORD","EGGY","TSHA","GAP","NBIX","OPLN","O","LITE","HUMA","TPL","CAVA","BETA","WXM","NBIZ","BIVI","ABSI","ANNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974868","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974868","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974868?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:22","pubTimestamp":1786533726,"startTime":"0","endTime":"0","summary":"Planet Green  shares were down more than 77% premarket Wednesday after an over 927% rise in the previous close.Silexion Therapeutics  stock was 54% lower after the company priced a $2.5 million securities offering.WF International  shares were down 31%, swinging from Tuesday's 98% rise.Snail  stock was 24% lower following its Q2 financial results.Concorde International Group  shares were down nearly 24%, paring Tuesday's 33% rise.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CIGL","BK4165","BK4212","SNAL","BK4139","BK4085","BK4086","SLXN","WXM","PLAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658941792","title":"Silexion Therapeutics Prices USD 2.5 Million Public Offering at USD 0.65 Per Share with Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2658941792","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658941792?lang=en_us&edition=fundamental","pubTime":"2026-08-12 08:01","pubTimestamp":1786492877,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics prices USD 2.5 million public offering at USD 0.65 per share with warrantsSilexion Therapeutics priced a USD 2.5 million public offering of 3,846,161 ordinary shares or equivalen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL6CPcTJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4112","NDAQ","SLXN","LU2095319765.USD","LU0314104364.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4585","SG9999014013.SGD","LU2210149790.SGD","BK4588","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658941796","title":"Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2658941796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658941796?lang=en_us&edition=fundamental","pubTime":"2026-08-12 08:01","pubTimestamp":1786492860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUATND69:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658372956","title":"Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658372956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658372956?lang=en_us&edition=fundamental","pubTime":"2026-08-11 03:30","pubTimestamp":1786390213,"startTime":"0","endTime":"0","summary":"WSW, NY, August 10th, 2026, FinanceWire Checkpoint inhibitors are drugs that remove the “brakes” cancer puts on the immune system, letting the body...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/immunotherapys-biggest-blind-spot-is-a-7-billion-market-silexion-may-have-a-way-in-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/immunotherapys-biggest-blind-spot-is-a-7-billion-market-silexion-may-have-a-way-in-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQQ",".IXIC","QQQJ","QDTE","TECS","MNQmain","QQQ","NVIW.SI","QYLG","TQQY","JEPQ","FTEC","BK4139","GPIQ","SLXN","NDX","QQQA","ONEQ","QLD","NQmain","QQQY","IYW","QQQE","QID","SQQQ","PSQ","QQQM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658672068","title":"Silexion Therapeutics Publishes Corporate Deck Spotlighting Sil204 siRNA Program Targeting KRAS-Driven Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2658672068","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658672068?lang=en_us&edition=fundamental","pubTime":"2026-08-09 20:41","pubTimestamp":1786279307,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancersSilexion highlighted SIL204, a second-generation siRNA designed to silence KRAS expression","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260809:nNDL4dLvQl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657629937","title":"Silexion Therapeutics files to sell ordinary shares, warrants, no amount given","url":"https://stock-news.laohu8.com/highlight/detail?id=2657629937","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657629937?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:45","pubTimestamp":1786135543,"startTime":"0","endTime":"0","summary":"16:40 EDT Silexion Therapeutics (SLXN) files to sell ordinary shares, warrants, no amount given Published first on TheFly – the ultimate source for...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-files-to-sell-ordinary-shares-warrants-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-files-to-sell-ordinary-shares-warrants-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SLXN","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656559067","title":"Silexion Reports Preclinical Sil204 Data Supporting Phase 2/3 Development in KRAS-Driven Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2656559067","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656559067?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:16","pubTimestamp":1785849372,"startTime":"0","endTime":"0","summary":"Silexion reports preclinical SIL204 data supporting Phase 2/3 development in KRAS-driven cancersSilexion Therapeutics reported new preclinical results for SIL204, extending earlier findings disclosed ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL3xJwvC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4112","NDAQ","SLXN","LU2095319765.USD","LU0314104364.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4585","SG9999014013.SGD","LU2210149790.SGD","BK4588","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656559706","title":"Silexion Therapeutics Corp - Announces Positive Preclinical Findings for Sil204 in Kras-Mutant Cancer Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2656559706","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656559706?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:15","pubTimestamp":1785849330,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN4411EJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656996183","title":"Silexion Therapeutics Director Amnon Peled Resigns for Personal Reasons","url":"https://stock-news.laohu8.com/highlight/detail?id=2656996183","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656996183?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:07","pubTimestamp":1785528442,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics director Amnon Peled resigns for personal reasonsProfessor Amnon Peled resigned from the board of Silexion Therapeutics for personal reasons, effective Aug. 1, 2026.The resignati","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL11FsMv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655895299","title":"Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655895299","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655895299?lang=en_us&edition=fundamental","pubTime":"2026-07-29 21:30","pubTimestamp":1785331817,"startTime":"0","endTime":"0","summary":"WSW, NY, July 29th, 2026, FinanceWire Silexion Therapeutics (NASDAQ:SLXN) just announced that it initiated its Phase 2/3 clinical trial of SIL204 a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/silexion-activates-first-site-in-phase-2-3-trial-targeting-kras-driven-pancreatic-cancer-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/silexion-activates-first-site-in-phase-2-3-trial-targeting-kras-driven-pancreatic-cancer-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSQ","NDX","QQQA","IYW","QQQ","QQQE","QLD","TQQQ","SLXN","QID","MNQmain","TQQY","IDNA","JEPQ","MEDX","NQmain","SQQQ","GPIQ","NVIW.SI","HYLG","QYLG","QQQM","QQQJ","TECS","NVIB","ONEQ","BK4139","QDTE","GDOC","FTEC","QQQY",".IXIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655864843","title":"Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2655864843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655864843?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA584Y51:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655861089","title":"Silexion Therapeutics Corp - Additional Israeli and German Sites Expected to Join Sil204 Phase 2/3 Trial in Coming Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2655861089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655861089?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA584Y51:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655861009","title":"Silexion Therapeutics Corp - Receives All Regulatory Approvals for Sil204 Trial in Israel as of July 29, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655861009","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655861009?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA584Y51:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.silexion.com","stockEarnings":[{"period":"1week","weight":-0.1272},{"period":"1month","weight":-0.8392},{"period":"3month","weight":-0.9123},{"period":"6month","weight":-0.979},{"period":"1year","weight":-0.9949},{"period":"ytd","weight":-0.981}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0206},{"period":"6month","weight":0.1111},{"period":"1year","weight":0.1921},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Moringa Acquisition Corp does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company focuses on pursuing opportunities in technology-based businesses or industries in Israel. Moringa Acquisition Corp was incorporated in 2020 and is based in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.016335},{"month":2,"riseRate":0.6,"avgChangeRate":-0.095221},{"month":3,"riseRate":0.8,"avgChangeRate":-0.040641},{"month":4,"riseRate":0.6,"avgChangeRate":-0.119987},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.024382},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.109699},{"month":7,"riseRate":0.833333,"avgChangeRate":0.002605},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.365766},{"month":9,"riseRate":0.6,"avgChangeRate":-0.230878},{"month":10,"riseRate":0.4,"avgChangeRate":-0.091257},{"month":11,"riseRate":0.4,"avgChangeRate":-0.018649},{"month":12,"riseRate":0.2,"avgChangeRate":-0.12005}],"exchange":"NASDAQ","name":"Silexion Therapeutics Corp","nameEN":"Silexion Therapeutics Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Silexion Therapeutics Corp(SLXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Silexion Therapeutics Corp(SLXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Silexion Therapeutics Corp,SLXN,Silexion Therapeutics Corp股票,Silexion Therapeutics Corp股票老虎,Silexion Therapeutics Corp股票老虎国际,Silexion Therapeutics Corp行情,Silexion Therapeutics Corp股票行情,Silexion Therapeutics Corp股价,Silexion Therapeutics Corp股市,Silexion Therapeutics Corp股票价格,Silexion Therapeutics Corp股票交易,Silexion Therapeutics Corp股票购买,Silexion Therapeutics Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Silexion Therapeutics Corp(SLXN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Silexion Therapeutics Corp(SLXN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction